The Administrative Core (AC) serves as the central coordinating center that manages and integrates the multiple program activities carried out at the ADCS and co-located facilities, and is necessary to maintain smooth operation of this complex grant program. Because the AC activities integrate with the activities of each of the other ADCS cores and committees it results in a multi-faceted approach that lends itself to communication and information sharing among all cores. The primary objective of the AC is to provide overall direction and oversight to the ADCS by working closely with its various cores and committees to accomplish program goals. The ADCS is a large, complex organization, with over 100 members at UCSD, 8 cores, 35 primary performance sites, dozens of additional sites, multiple ongoing trials, collaborations with multiple companies, and contracts with many vendors. It is primarily an academic organization, but performs all of the activities required by multicenter trials, with an in-house data management system, biostatistics, clinical operations, regulatory oversight, medical and safety management, and onsite and remote clinical monitoring. Smooth operation requires, in addition to experience and expertise, efficient and effective management, standard operating procedures and quality assurance programs, and effective communications. The standing committees, which exist throughout the grant period, contribute to all grant activities. The Committees budgeted within the Administrative Core are the Internal Ethics Committee, the Clinical Dementia Rating Scale Committee, and the Instrument Committee with its five subcommittees.
There is no greater health care need than the development of effective therapy for AD. With aging baby-boomers now at the age of risk for AD, the epidemic will accelerate. The ADCS maintains an optimized infrastructure to support its trials, as well as trials and longitudinal studies funded by other grants, and to facilitate sharing of data, specimens and methods.
|Marquié, Marta; Verwer, Eline E; Meltzer, Avery C et al. (2017) Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. Acta Neuropathol Commun 5:75|
|Donohue, Michael C; Sperling, Reisa A; Petersen, Ronald et al. (2017) Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA 317:2305-2316|
|LaPoint, Molly R; Chhatwal, Jasmeer P; Sepulcre, Jorge et al. (2017) The association between tau PET and retrospective cortical thinning in clinically normal elderly. Neuroimage 157:612-622|
|Dekhtyar, Maria; Papp, Kathryn V; Buckley, Rachel et al. (2017) Neuroimaging markers associated with maintenance of optimal memory performance in late-life. Neuropsychologia 100:164-170|
|Schultz, Aaron P; Chhatwal, Jasmeer P; Hedden, Trey et al. (2017) Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. J Neurosci 37:4323-4331|
|Buckley, R F; Sparks, K P; Papp, K V et al. (2017) Computerized Cognitive Testing for Use in Clinical Trials: A Comparison of the NIH Toolbox and Cogstate C3 Batteries. J Prev Alzheimers Dis 4:3-11|
|Langa, Kenneth M; Larson, Eric B; Crimmins, Eileen M et al. (2017) A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. JAMA Intern Med 177:51-58|
|Sawda, Christine; Moussa, Charbel; Turner, R Scott (2017) Resveratrol for Alzheimer's disease. Ann N Y Acad Sci 1403:142-149|
|Raman, Mekala R; Tosakulwong, Nirubol; Zuk, Samantha M et al. (2017) Influence of preeclampsia and late-life hypertension on MRI measures of cortical atrophy. J Hypertens 35:2479-2485|
|Jacobs, Diane M; Ard, M Colin; Salmon, David P et al. (2017) Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimers Dement (N Y) 3:531-535|
Showing the most recent 10 out of 484 publications